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It may all have started as a pleasant walk, a careless journey, free from the dreaded 
expectation that one can feel today. 
However, step by step, you went forward, and before even realising it, you started climbing. 
Past fellows are now gone. They've taken another path, lost in the fog of possibilities. Only a 
few remain, that have started climbing on their own. 
So look up now, and as you climb one rock after the other, know there is joy in this struggle. 
The peak, hidden by a veil of mist, is never to be seen, nor conquered, for it is merely but an 
illusion. 
[…] 
As you sweat, bleed and wonder what other paths could have been, you may find what you 
were looking for. The fulllfillness. The feeling of being exactly where you belong, peace of 
mind within reach. 
Yet, this is another gamble on the lottery of paths. Despite all you have given, all your efforts 
and all your strength, you might end up finding nothing but bitterness. 
So climb, and feel it. And if you look down, remember to smile at your past blood and sweat-
stained rocks that stand below, for they have carved what you are. 
 
- Anachronism,  Hidden  Relief 
 
  

  
ABSTRACT 
Ubiquitination is a post-translational modification achieved by an enzymatic cascade. This 
post-translational modification is involved in many crucial cellular processes across different 
cellular compartments such as protein turnover via the ubiquitin proteasome system and 
various signaling pathways from the DNA damage response to the immune response. 
Ubiquitin has seven lysine residues (Lys 6, 11, 27, 29, 33, 48 and 63) onto which other 
ubiquitin moieties can be conjugated, forming ubiquitin chains of different types. These 
different ubiquitin chains can have different functions and the relationship between both is 
often referred to as “the ubiquitin code”. Although the enzymatic cascade leading to 
ubiquitination of proteins is well described, the ubiquitin code remains largely unresolved. 
Accumulation of insoluble ubiquitinated proteins is a hallmark of neurodegenerative 
disorders such as Parkinson’s and Alzheimer’s disease, making the study of these cellular 
processes relevant to human health. Specific proteins can also impair the function of the 
proteasome such as progerin in the Hutchinson-Gilford Progeria Syndrome (HGPS). 
The importance of ubiquitination in many cellular processes and its 
involvement in many human pathologies inspired us to develop an inducible ubiquitination 
system that could be used as a tool to better understand the ubiquitin code and its role in 
different cellular compartments. In paper I, we have engineered a ubiquitin ligase, ProxE3, 
which assembles specific ubiquitin chain (lysine 63) onto a fluorescent substrate. We have 
used this tool to generate ubiquitin chains on the surface of mitochondria and investigate 
mitophagy, more precisely if lysine 63 (K63) ubiquitin chains are sufficient to trigger 
aggregation of mitochondria or mitophagy. Upon successful ubiquitination of the surface of 
mitochondria by ProxE3 and depolarization of mitochondria by carbonyl cyanide m-
chlorophenyl hydrazone (CCCP), peri-nuclear clustering of mitochondria was observed but 
not mitophagy. The lack of mitophagy indicates that either the amount of K63 ubiquitination 
is insufficient in our system, that other types of ubiquitin chains are required, that a specific 
substrate need to be ubiquitinated or that the PINK1 feedforward loop is essential for 
mitophagy. Nonetheless, this work presents a valid tool for studies of ubiquitination in living 
cells, while reaffirming the complexity of the regulation of mitophagy. 
In paper II, we were interested in ubiquitination in a different cellular 
compartment: the nucleus. In this paper, we used a human cell-line expressing a fluorescent 
proteasomal substrate to investigate if the ubiquitin-proteasome system was impaired upon 
overexpression of progerin. Progerin is a mutated form of lamin A which is the cause of 
HGPS. It has been suspected that progerin might inhibit the catalytic activity of the 
proteasome, which could lead to neuronal dysfunction. However, we did not detect 
proteasomal impairment in human cells overexpressing progerin compared to wild-type 
lamin A. This observation is further supported by the lack of progerin/lamin A inclusions in 
hippocampal neurons of HGPS mice, implying that the ubiquitin/proteasome system is not 
sensitive to the expression of progerin in neurons of mice. 
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1 INTRODUCTION 
 
A cell is able to respond to its environment via a plethora of modifications of its genome and 
proteome, for instance translation regulations by DNA methylation and protein post-
translational modifications. Post-translational modifications are diverse and can change 
proteins structure and functions chemically (phosphorylation, acetylation, methylation, S-
nitrosylation, thiolation, S-sulfonation, glycosylation, acylation, prenylation, AMPylation, ADP-
ribosylation and S-sulfenylation) or via polypeptides (ubiquitination, ubiquitin-like, neddylation 
and SUMOylation) [1]. The primary focus of my thesis is ubiquitination and its involvement in 
the fate of proteins in different cellular compartments. Other post-translational modifications 
are beyond the scope of this work, unless they are involved in a relevant cross-talk with 
ubiquitination, such as acetylation, phosphorylation [2,3] and SUMOylation [4]. 
 
1.1 UBIQUITIN 
 
The ubiquitin is a small 76 amino acid-long protein (see Fig. 1), which was first characterized 
for its role in post-translational modification of histones [5,6] but also ubiquitin-dependent 
proteasome degradation [7] and subsequently, regulation of gene expression [8–11] and DNA 
damage response [12,13]. Ubiquitination has been further shown to be a major post-
translational modification involved in most cellular processes such as apoptosis [14], the cell-
cycle, endocytosis, inter-cellular communication [15,16], macroautophagy (referred to as 
autophagy) and mitophagy. The role of ubiquitination in autophagy and mitophagy will be 
further discussed in this introduction. 
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FIGURE 1. Structure of ubiquitin. Image of 1UBQ [17] created with UCSF Chimera [18]. The 
N-terminal methionine (MET) is colored in red, while the C-terminal glycine (Gly) is colored in 
dark blue and lysine (Lys) residues in purple. 
 
1.2 UBIQUITINATION 
 
The cellular process known as ubiquitination is a reversible post-translational modification 
driven by an enzymatic cascade resulting in ubiquitin being conjugated onto a specific lysine 
residue of a substrate [19] (see Fig. 2). At the beginning of this enzymatic cascade [7], the 
ubiquitin activase (E1) acetylates the ubiquitin in an ATP dependent manner. After this step, 
the activated ubiquitin will be transferred via a trans(thio)esterification reaction from the E1 
onto a ubiquitin conjugase (E2). Finally, a ubiquitin ligase (E3) specific for a substrate will 
facilitate the conjugation of the ubiquitin by the E2 onto the substrate, although some E3 
ligases have themselves an intrinsic catalytic activity that directly mediates the transfer of the 
ubiquitin. This final step results in the formation of an isopeptide bond between a lysine of the 
substrate and the C-terminal glycine of ubiquitin. The final conjugation step of a ubiquitin 
moiety unto a substrate varies depending on the type of E3, as discussed later in this 
introduction. A ubiquitin moiety can be conjugated onto another ubiquitin moiety’s lysine 
residues K6, 11, 27, 29, 33, 48 and 63 (see Fig. 1). Sequential conjugation events result in 
the formation of ubiquitin chains. While hundreds of these E3 are known to exist [20], only two 
E1 (UBA1/UBE1 and UBA6) [21,22] and about forty E2s have been found [23], making E3 
ligases attractive therapeutic targets in a wide range of diseases due to their diversity and 
target specificity [24–26]. 
  3 
 
 
 
FIGURE 2. Ubiquitination process and resulting types of ubiquitination. Ubiquitin 
activase (E1) is colored in blue, ubiquitin conjugase (E2) is colored in purple, ubiquitin ligase 
(E3) is colored in red, ubiquitin (Ub) is colored in orange and the substrate (Sub) is colored in 
green. 
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1.3 UBIQUITIN LIGASES 
 
Three main families of E3s are known so far. The Really Interesting New Gene (RING) 
[27,28] the Homologous to E6AP C-terminus (HECT) [29–31] and the RING-in-between-
RING (RBR) [32–34] family (see Fig. 3). The RING E3 facilitates the conjugation of ubiquitin 
as described previously. It functions as a scaffold protein, bringing the E2 in a closed 
proximity with the substrate [23], thus facilitating the transfer of the ubiquitin moiety from the 
E2 to the substrate. RING E3s therefore lack a catalytic domain. Unlike the RING family, the 
HECT and RBR families possess an intrinsic catalytic activity. In the case of HECT E3, the 
catalytic cysteine in the HECT domain forms a thioester bond with ubiquitin before catalyzing 
the formation of the isopeptide bond between the ubiquitin and the lysine residue in the 
substrate. On top of their HECT domain, most E3 of this family have up to four WW domains 
and a C2 domain involved in protein/protein interactions, including substrate recognition. 
Since HECT E3s have an intrinsic catalytic activity, they are able to auto-ubiquitinate as a 
regulatory mechanism if intra-molecular interactions between the HECT domain and a WW 
domain or C2 domain are disrupted, leading to their own degradation [35–37]. HECT ligases 
also have an inactive closed conformation when their WW or C2 domains are interacting 
with their HECT domain, thus reducing the accessibility of the substrate to the WW domains 
or the E2 to the HECT domain. Such interaction can be intra-molecular [38] or inter-
molecular in the case of the NEDD4 family member Smurf1, which forms inactive dimers 
[39]. It is also worth mentioning that more evidence is pointing towards sequential formation 
of ubiquitin chains by HECT E3 as they transfer one ubiquitin moiety at a time from the 
E3~Ub to the substrate [40–42]. The sequential-addition model of ubiquitin supports chain 
elongation and formation of branched ubiquitin chains [43]. This sequential formation of 
ubiquitin chains is in opposition with the en bloc ligation of a chain. During this process, a 
chain is first assembled on the E2, then transferred to the active cysteine of an E3 and finally 
transferred to the substrate [44]. The chain specificity of HECT E3s is purely dependent on 
their HECT domain and not the E2 that donates the ubiquitin to their catalytic site [40]. 
Mechanistically, RBR presents features of RING and HECT E3s. This family of E3s have 
two RING domains (RING 1 and RING 2) separated by an “in-between RING domain” (IBR). 
RING 1 is involved in the binding of E2~ubiquitin while RING 2 is the catalytic domain 
involved in the transfer of ubiquitin on the substrate, while the IBR is helping both of these 
functions.  
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FIGURE 3. Main families of ubiquitin ligases. Simplified representation of ubiquitination of 
a substrate by A) RING ubiquitin ligases B) HECT ubiquitin ligases and C) RBR ubiquitin 
ligases. Ubiquitin conjugase (E2) is colored in purple, ubiquitin ligases (E3) are colored in red, 
ubiquitin (Ub) is colored in orange and the substrate (Sub) is colored in green. Bent arrows 
represent the transfer of ubiquitin. 
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1.4 UBIQUITIN CHAIN TYPES 
 
A single ubiquitin moiety can be conjugated onto a substrate (see Fig. 2), which is referred to 
as monoubiquitination. Ubiquitin moieties can also be linked to each other via their lysine 
residues (K6, K11, K27, K29, K33, K48 and K63) or their N-terminal end (M1-linked 
ubiquitination also known as linear ubiquitin chains) to form ubiquitin chains. This is known as 
polyubiquitination. These ubiquitin chains can be homogenous, mixed or branched with 
different types of ubiquitin chains having different functions, resulting in the “ubiquitin code” 
[45]. Homogenous chains are made of ubiquitin conjugated to each other via the same linkage. 
Depending on the linkage, a polyubiquitin chain will have a different structure. For example, 
K48 linked chain are more compact than K63 chains, which are very similar to linear ubiquitin 
chains. With this example in mind, and since structure influences function, K48 homogenous 
ubiquitin chains are known to target for protein degradation via the proteasome [46], while K63 
homogenous chains have been traditionally shown not to be involved in proteasomal 
degradation [47] but fulfill non-proteolytic roles, such as the DNA damage response [48] or 
endocytosis [49,50]. However, the distinction between proteolytic and non-proteolytic ubiquitin 
chains becomes less clear as progress towards understanding of the ubiquitin code is made. 
It has for example been shown that not only K48 linkages but also  K6, K11, K27, K29 and 
K33 chains are increased in cells upon inhibition of the proteasome [47]. Furthermore, K48 
ubiquitin chains can have non-proteolytic roles in regulation of transcription factors [51], while 
K63 chains can target proteins for lysosomal degradation [52] and K63/K48 mixed chains can 
target for proteasomal degradation [53].  These mixed ubiquitin chains consist of a mix of 
ubiquitin linkages within a chain and can even branch out. Recently, branched ubiquitin chains 
have been shown to be assembled in two phases by the HECT E3 WWP1. First a 
unidirectional K63 ubiquitin chain is assembled on the substrate and in a second step, mixed 
branches are added to the ubiquitin chain [43]. Mixed and branched ubiquitin chains render 
the understanding of the ubiquitin code even more challenging, as it complicates the 
ubiquitination landscape considerably. For example, while homogeneous K11 ubiquitin chains 
do not target proteins involved in the cell-cycle for degradation by the proteasome, mixed 
K11/K48 ubiquitin chains do [54,55]. To complicate things even further, mixed chains have 
been shown to have different conformations depending on the position of a given linkage in a 
tri-ubiquitin chain (see Fig. 2, mixed ubiquitin chain), which affects the cleavage rate of specific 
ubiquitin linkages by deubiquitinating enzymes [56].  
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1.5 REGULATION OF UBIQUITINATION AND DEUBIQUITINATING ENZYMES 
 
Ubiquitination regulates many cellular processes, as discussed previously, and it is therefore 
a reversible and tightly regulated process itself. HECT E3 activity is regulated by inter- or intra-
molecular interactions that keep the HECT E3 in an inactive conformation and also prevents 
auto-ubiquitination. Substrate adaptor subunits of E3 ligases, such as Cdh1 (from the 
multisubunit E3 APC/C), have also been shown to be able to lift inhibitory inter-molecular 
interactions to activate other E3s [39] or to inhibit E3s by facilitating inhibitory intra-molecular 
interactions [57], both independently of APC/E3 activity. Other ways of regulating 
ubiquitination of substrates are through deubiquitinating enzymes (DUBs). These proteases 
target ubiquitin conjugates and ubiquitin chains and reverse the ubiquitination modification. 
Most DUBs are cysteine proteases and belong to five different families based on their catalytic 
domains: ubiquitin C-terminal hydrolase (UCH), ubiquitin-specific protease (USP), Otubain 
protease (OTU) and Josephin domain DUBs [58]. A smaller number of DUBs are 
metalloproteases and belong to the JAB1/MPN/Mob34 metalloenzyme (JAMM) family. The 
substrate specificity of DUBs can depend on a given type of ubiquitin chain - for example the 
yeast DUB Ubp2 cleaves K48 ubiquitin chains rather than K63 [59] - while mammalian USP14 
cleaves K48 ubiquitin chains but not K63 [60]. However, DUBs can also be specific for a 
certain ubiquitinated target. For example, the DUB USP8 deubiquitinates and stabilizes the 
RING E3 ligase NRDP1. NRDP1 is known to auto-ubiquitinate leading to its own degradation 
in absence of USP8 [61]. Ultimately, the specificity of a DUB depends on both the ubiquitin 
chains and the ubiquitin-modified target. This is, for example, illustrated by USP8, which 
specifically removes K6 ubiquitin chains conjugated on the RBR E3 PARKIN [62,63], which is 
involved in mitophagy. Interactions between DUBs and E3 paint a complex picture of 
ubiquitination as this can result in situation where ubiquitin chains are not only conjugated or 
cleaved, but instead edited with one linkage being replaced for another linkage [64,65].  
 
The binding of DUBs to ubiquitin is possible through interaction between the ubiquitin and the 
ubiquitin binding domain (UBD) of a DUB. UBDs are extremely diverse: about twenty different 
UBDs domains have been described so far [66]. These UBDs subclasses can be of various 
structure such as alpha-helical, Zinc finger, Plekstrin-like, Src homology 3 or WD40 beta-
propeller. UBDs are found not only in DUBs but also in many other proteins involved in 
ubiquitin-dependent pathways. Beside their well-established function in the NF-kB pathway 
[67] and DNA damage response [68], UBDs are found in molecular chaperones such as 
p97/VCP (Cdc48 in yeast) cofactors Ufd1, Npl4 and p47 [69,70], which are involved in 
membrane fusion, endoplasmic reticulum (ER)-associated degradation (ERAD), export of 
misfolded proteins from the ER and proteasomal degradation [71,72]. UBDs are also found in 
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proteins involved in endocytosis such as epsins, EPS15 and EPS15R [73,74]. In addition, 
autophagic adaptors such as p62/SQSTM1 [75] and NBR1 [76] possess UBDs, allowing for 
autophagic degradation of ubiquitinated substrates. Finally, shuttle factors involved 
proteasomal degradation and intrinsic ubiquitin receptors of the proteasome contain UBDs.  
 
1.6 UBIQUITIN IN THE NUCLEUS 
 
Complementarily to its nuclear functions in DNA damage response, histone modifications and 
gene regulation, as mentioned earlier in this introduction, ubiquitin can regulate subcellular 
localization, including nuclear localization of proteins, through monoubiquitination [77]. For 
example, the Fanconi Anemia Complementation Group 2 (FANCD2) protein, involved in DNA 
damage response, requires monoubiquitination on it lysine residue 561 in order to localize to 
nuclear foci in response to DNA damage. The UPS has also been described to be enriched in 
the nucleus of specific cell types [78], such as certain populations of pyramidal neurons and 
cortical neurons in rats [79]. The nuclear localization of proteasomes in mammalian cells has 
been shown to occur both rapidly during mitosis and slowly by diffusion through the nuclear 
envelope [80]. Nuclear proteasomes have been shown to be important for degradation of 
transcription factors, proteins from the nuclear envelope and misfolded proteins [81–83]. 
Components of the nuclear envelope such as lamin A have also been shown to be degraded 
by another proteolytic process, which occasionally relies on ubiquitin: autophagy [84]. 
Mutations in lamin A – the mutant protein being referred to as progerin – are responsible for 
the Hutchinson-Gilford progeria syndrome (HGPS) [85].  In the context of HGPS, inducing 
autophagy via rapamycin treatment [86] has been shown to alleviates phenotypes [85,87]. 
Similarly, targeting autophagy or the UPS in neurodegenerative disorders such as 
Parkinson’s, Alzheimer’s, Huntington’s disease and aging in general, which are all conditions 
where misfolded proteins accumulate in the nucleus of neurons, has been proposed as a 
therapeutic approach worth investigating [88–90]. In short, by harnessing ubiquitin signaling, 
it may be possible to induce degradation of proteins involved in pathologies [91]. Although this 
idea is not new, it did not translate into therapies used in a clinical setting so far. This is 
probably partially due to the complexity of the ubiquitin code and the large amount of time 
necessary to develop the molecular tools required for understanding it. 
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FIGURE 4. Simplified 26S yeast proteasome structure and proteasomal degradation of 
a protein. Subunits interacting with ubiquitin (Rpn10 and Rpn13) are represented with a dark 
red border. Rpn11, which deubiquitinates the target protein, is colored in pink. The lid of the 
19S regulatory particle is colored in dark purple. The base of the lid is colored in lilac. The 
alpha ring is colored in orange. The beta ring is colored in yellow. 
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1.7 UBIQUITIN PROTEASOME SYSTEM 
 
1.7.1 Structure of the proteasome 
 
The mammalian 26S proteasome is a cylindrical 2.5 MDa protein complex, composed of a 
20S central core particle and capped by two 19S regulatory particles (see Fig. 4). This protein 
complex is made of 33 subunits. The core particle is composed of four rings: two β rings 
forming the center of the hollow cylinder, each flanked by an a ring. Each ring constitutes of 
seven α or β subunits. Proteolytic function is achieved by three β subunits in each beta ring: 
b1, b2 and b5, which have a caspase-like, trypsin-like and chymotrypsin-like activity, 
respectively. These different activities allow for rapid proteolysis of almost any protein into 
polypeptides of 7 to 8 amino-acids on average [92]. 
 
1.7.2 Substrate recognition 
 
1.7.2.1 Proteasomal subunits 
 
Proteasomal substrate recognition is mediated by different proteins: three proteasomal 
subunits and several shuttling factors containing Ubiquitin-like (UBL) and ubiquitin-associated 
(UBA) domains. The proteasomal subunits RPN1, PSMD4 and ADRM1 in mammals (Rpn1, 
Rpn10 and Rpn13 in yeast, respectively) are part of the 19S regulatory particle, but only Rpn1 
seems essential for growth in yeast [93]. Recognition of substrate by RPN1 is mediated by the 
receptor site T1 in the first toroidal domain of RPN1, which binds preferably K6 and K48-linked 
diubiquitin and the UBL domain of RAD23, a shuttle factor involved in targeting of ubiquitinated 
substrates. These interactions have been shown both in S. cerevisiae and humans [94]. 
PSMD4/Rpn10, was the first proteasomal ubiquitin receptor identified [95]. Ubiquitin 
recognition is mediated by the UIM (an alpha-helical UBD) of Rpn10 and modulated by 
ubiquitination of Rpn10 itself. In yeast, monoubiquitination of Rpn10 by Rsp5 (a NEDD4-like 
E3) reduces the affinity of Rpn10 for ubiquitin and ubiquitinated substrates [96]. 
Deubiquitination of monoubiquitinated Rpn10 by the DUB Ubp2 counters the effects of Rsp5. 
ADRM1/Rpn13 recognizes monoubiquitin and K48-linked diubiquitin through its N-terminal 
plekstrin-like domain, which also binds RPN2, anchoring ADRM1/Rpn13 to the 19S particle 
[97]. The C-terminal half of human ADRM1 binds and activates the DUB UCH37/UCHL5 by 
lifting its autoinhibition [98,99], effectively recruiting it to the proteasome in order to trim 
ubiquitin chains from the ubiquitinated substrates targeted for degradation [100], thereby 
recycling ubiquitin and maintaining the cellular free ubiquitin pool, like PSDM14/POH1/Rpn11 
[101] and Ubp6 [60,102,103]. Similarly to PSMD4/Rpn10, ADRM1/Rpn13 interacts with 
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shuttling factors with UBL and UBA domains such as RAD23, DSK2 [97] and PLIC-2 [94]. 
Similarities with PSMD4/Rpn10 do not end there, as the affinity for ubiquitin and ubiquitin 
substrates of ADRM1/Rpn13 can also be modulated by the HECT E3 UBE3C/HUL5. This E3 
can polyubiquitinate PSMD4/Rpn10, resulting in decreased  binding of ubiquitinated 
substrates to the proteasome [104].  
1.7.2.2 Shuttling factors 
 
UBL/UBA shuttling factors that are not directly bound to the proteasome (unlike Rpn1, Rpn10 
and Rpn13) can exist in an auto-inhibited cis or trans state. Three shuttle factors are known in 
yeast: Rad23, Dsk2 and Ddi1. The human genome encodes several other shuttling factors 
[105], namely: HR23A and HR23B (both homologues to Rad23 in yeast), DDI1 and DDI2 [106] 
(both homologues to Ddi1 in yeast), PLIC-1, PLIC-2 (homologues to Dsk2 in yeast), A1Up, 
KPC2, NUB1, NUB1L and p62.  These shuttling factors act as adaptors presenting a protein 
for proteolysis while escaping proteolysis themselves [107,108]. They bind a ubiquitinated 
substrate with their UBA domain and the proteasome with their UBL domain. After being 
shuttled to the 19S regulatory subunit, proteins targeted for proteasomal degradation are 
deubiquitinated by proteasome-associated DUBs and simultaneously translocated from the 
base of the 19S regulatory particle towards the 20S core particle in an ATP-dependent process 
driven by an AAA-ATPase hetero-hexameric ring composed of Rpt1 to 6 in S. cerevisiae and 
PSMC 1 to 6 in humans [109]. The proteasomal substrate is then hydrolyzed by the 20S core 
particle as the AAA-ATPase ring progressively feeds the protein into the proteolytic chamber 
of the 20S core particle. 
 
1.7.3 Alternative forms of proteasome 
 
It is worth mentioning that several types of proteasome have been described harboring 
different types of regulatory particles beside the canonical 19S. For example, the 19S 
regulatory particle of the 26S proteasome can be replaced by an 11S particle [110] composed 
of  proteins belonging to the REG family: the REGa/b and REGg subunits [111,112]. A 19S 
particle associated with these REG subunits, thus forms a REG proteasome. The 
REGg proteasome for example, is involved in immunity and  cancer progression [113,114]. 
Alternatively, a less known and characterized proteasome can be formed with PA200 as its 
regulatory particle [115]. 20S core particles lacking the 19S regulatory particle have also been 
described in degradation of proteins damaged by oxidation stress [116] and proteins with large 
unstructured regions [117]. Other types of proteasomes can have a different composition of 
20S core particle. For example, the immunoproteasome harbors three different b subunits in 
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its 20S core particle, their expression being induced by IFN-g: b1i, b2i and b5i [118,119]. These 
b subunits allow for degradation of the substrate protein into oligopeptides of 8-10 amino-acids 
which can then be presented as antigens by major histocompatibility complex (MHC) class 1 
molecules [120]. Although the immunoproteasome is not essential for antigen presentation 
and the regular 26S proteasome plays a similar role in antigen presentation, the 
immunoproteasome has been shown to be critical for the generation of specific cytotoxic T 
lymphocytes epitopes [121]. Some of these alternative forms of proteasome have also been 
shown to degrade proteins in a ubiquitin-independent fashion. This is the case for PA200 
containing proteasomes involved in acetylated histone degradation [122,123], REGg 
proteasomes degrading the cyclin-dependent kinase inhibitor p21 [124] and steroid receptor 
SRC-3/AIB1 [125] and free 20S proteasome degrading oxidized proteins [116]. 
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1.8 UBIQUITIN IN AUTOPHAGY 
 
1.8.1 Core principles of autophagy 
 
1.8.1.1 Cross-talk between UPS and autophagy 
 
Beside proteasomal degradation, cells have an alternative route for protein degradation, 
namely autophagy, a tightly regulated and evolutionary well conserved process in which more 
than 30 autophagy-related (ATG) proteins are involved [126]. Proteins are only one type of 
macromolecules being degraded by autophagy, as autophagy engulfs part of the cytoplasm 
and organelles for bulk degradation into the lysosome. This bulk degradation is key to cellular 
homeostasis and recycling of cellular components (proteins, lipids, organelles and 
carbohydrates). However, autophagy is not limited to passive engulfment of cytoplasm and 
organelles. It can be selective by targeting specific substrates for degradation via autophagy 
receptors, both in a ubiquitin-dependent and -independent fashion [127]. Although autophagy 
and the UPS are presented in two different parts of this introduction, these two processes are 
not strictly separated in cells and have been shown to occasionally intersect. The histone 
deacetylase 6 (HDAC6), for example, has been identified as a compensatory link between 
autophagy and UPS when the proteasome is impaired in D. melanogaster [128]. In this 
situation, HDAC6 is involved in the autophagic degradation of aggregation-prone proteins. 
HDAC6 has also been shown to act as an adaptor between the dynein motor complex and 
K63 polyubiquitinated proteins in mammals, guiding these proteins along microtubules 
towards the microtubule organizing center, an area where autophagy is very active (rich in 
autolysosomes) [129]. Other chaperones and co-chaperones containing UBA/UBL, such as 
BCL-2-associated athanogene 1 and 3 (BAG1 and BAG3), two HSC/HSP70 co-chaperones, 
have been shown to be a switch between proteasomal and autophagic degradation [130]. The 
work of Gamerdinger et al. indicates that BAG3 forms a complex with p62/SQSTM1, which 
promotes degradation of polyubiquitinated proteins via autophagy, especially in aging cells 
[130]. On the other hand, cells expressing mostly BAG1 are degrading the vast majority of 
their polyubiquitinated proteins via the proteasome route. Another chaperone-like protein, 
p97/VCP, which is involved in proteasomal degradation as mentioned earlier, as well as in 
autophagy. In fact, mutations of p97/VCP lead to inclusion body myopathy associated with 
Paget's disease of the bone and frontotemporal dementia (IBMPFD), an autosomal dominant 
disease in which accumulation of autophagic structures are observed in patients. The UPS, 
however, remains functional in cells expressing mutant p97/VCP responsible for IBMPFD 
[131]. 
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1.8.1.2 The steps of autophagy 
 
The first step of autophagy is the initiation, followed by vesicle nucleation, elongation, fusion 
and finally degradation. The initiation begins with metabolic stimuli such as nutrients 
deprivation [132]. Alternatively,  rapamycin treatment can also initiate autophagy [86]. Both 
types of stimuli inhibit the mTORC1 complex (composed among others of mTOR and Raptor). 
This inhibition then activates the serine-threonine kinase ULK1, which is no longer 
phosphorylated by the mTORC1 complex. The ULK1 complex (formed of ULK1, ATG13, 
ATG101 and FIP200) is then activated by phosphorylation of ATG13 and FIP200 by ULK1 
[133], which leads to the recruitment of the Beclin-1-Vps34 complex. The vesicle nucleation 
step then starts as the Beclin-1-Vps34 complex localizes at the formation site of the 
phagophore, a cup-shaped membrane (see Fig. 5). It is during this step that a component of 
the Beclin-1-Vps34 complex, Ambra1 (normally phosphorylated and inhibited by mTORC1 
under non-autophagic conditions), recruits the RING E3 TRAF6 which participates in ULK1 
K63 ubiquitination [134]. K63 ubiquitination of ULK1 induces its self-association and further 
stabilization, which in turn leads to Beclin-1 phosphorylation. Beclin-1 phosphorylation 
enhance the activity of the ATG14L-Beclin-1-Vps34-Vps15 complex [135], allowing Vps34 to 
produce phosphatidylinositol 3-phosphate (PI(3)P). This increase of PI(3)P leads to 
recruitment of effector proteins such as DFCP1 [136], WIPI1 [137], WIPI2 [138] and 
subsequent formation of the omegasome [136]. Next the vesicle elongation is driven by ATG 
proteins in a process reminiscent to ubiquitination: ATG12-ATG5-ATG16L on one hand and 
LC3/Atg8 on the other hand. ATG12 is activated by the E1-like ATG7, then transferred onto 
the E2-like ATG10 and finally conjugated to a lysine residue of ATG5. The ATG12-ATG5 then 
binds ATG16L. Running parallel to this process, LC3-I (Atg8 in yeast) is conjugated to 
phosphatidylethanolamine (PE), forming the lipid bound LC3-II. This conjugation process is 
catalyzed by ATG7 (E1-like) and ATG3 (E2-like). While the omegasome is elongating, 
engulfment of target proteins and organelles is facilitated by autophagy receptors such as 
p62/SQSTM1 [139], NBR1 [76], optineurin (OPTN) [140], NDP52 [141], and Alfy [142]. These 
autophagy receptors can recognize ubiquitinated substrates and target them for autophagy, 
i.e.: K63 polyubiquitinated substrates can be recognized by p62 and OPTN [143]. However, 
autophagy receptors are also mediating ubiquitin-independent recognition of autophagy 
substrates. For example, although OPTN is specific of K63 polyubiquitinated substrates, it has 
also been shown to recognize protein aggregates with its C-terminal coiled-coil domain, thus 
playing a role in ubiquitin-independent clearance of aggregated proteins via autophagy [144]. 
During the final step of autophagy, the omegasome closes, forming an autophagosome, which 
will then fuse with the lysosome, forming the autolysosome (in mammals) in which engulfed 
cellular components are degraded. The fusion step is different for yeast, however.  
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FIGURE 5. Autophagy steps from initiation to fusion and degradation. Inhibiting and 
activating phosphorylation are represented as a blue circle with the letter “P” inside. K63 
ubiquitination is represented as an orange circle with “Ub” written in it. 
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Autolysosome [145]. It is worth mentioning that the source of the constitutive membrane of 
omegasomes and autophagosomes are debated to this day [146], although the ER [147], the 
Golgi apparatus, the plasma membrane and mitochondria [148] are suspected to participate 
in autophagosome formation. 
 
1.8.2 Mitophagy 
 
1.8.2.1 Mitophagy: a specific autophagy pathway 
 
The previous part of this introduction discussed core principles of autophagy, but several types 
of autophagy exist depending on the target. Some of these specific autophagy pathways are 
dependent on Ras-related proteins RAB9A and RAB9B but do not rely on ATG5 and ATG7 
unlike conventional autophagy [149–151]. Mitophagy is one of these specific autophagic 
pathways. It is a degradation pathway dedicated to recycling components of damaged 
mitochondria in a ubiquitin-dependent and -independent manner [127] and prevents oxidative 
stress generated by damaged mitochondria and cell death [152]. Various types of stresses 
can induce mitophagy such as hypoxia [153], starvation [154] or proteotoxic stress in the 
mitochondrial matrix [155]. Mitophagy has been primarily studied in a stress- or disease-
related context, however, recent work using transgenic mice expressing the fluorescent 
reporter mt-Keima or mito-QC have shown that a basal level of mitophagy occurs and vary 
widely between organs and cell types [156,157]. As mentioned earlier, the RBR E3 PARKIN 
is involved in mitophagy, although PARKIN-independent forms of mitophagy have been 
described.  
 
1.8.2.2 PARKIN-dependent mitophagy 
 
PARKIN is activated during ubiquitin-dependent mitophagy by the PTEN-induced putative 
kinase 1 (PINK1). In healthy mitochondria, PINK1 is transported from the outer mitochondrial 
membrane (OMM) to the inner mitochondrial membrane (IMM) thanks to its N-terminal 
mitochondrial targeting signal (MTS) via the translocase of the outer membrane (TOM) and 
translocase of the inner membrane (TIM) complexes [158]. Several proteases participates in 
the processing and degradation of PINK1 in the IMM: the mitochondrial processing peptidase 
(MPP) [159], AFG3L2 (a subunit of mitochondrial AAA protease in human) [160] and 
Rhomboid-7/presenilin-associated rhomboid-like protease (Rho-7/PARL) [161]. Processing 
by these proteases have been shown to release PINK1 in the cytosol where it is degraded by 
the proteasome [162]. An alternative route for PINK1 degradation after processing by these 
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three proteases could happen in the mitochondrial matrix where it is further broken down by 
the protease Lon [163]. Upon decrease of mitochondrial potential due to mitochondrial 
damages, import of PINK1 through the TOM complex becomes impossible. PINK1 is therefore 
stabilized on the OMM and activated via auto-phosphorylation. Once activated, PINK1 
phosphorylates ubiquitin and the UBL domain of PARKIN, leading in turn to interaction of 
activated PARKIN with phospho-ubiquitin and translocation of PARKIN to the surface of the 
mitochondria. A feedforward mechanism is thus created, where PINK1 lifts the auto-inhibition 
of PARKIN and phosphorylates ubiquitin, leading PARKIN to build polyubiquitin chains on the 
surface of mitochondria, which will then be phosphorylated by PINK1, resulting in recruitment 
and activation of more PARKIN. Furthermore, PARKIN might help stabilizing PINK1 [164], 
thus creating a positive feedback loop. It is unclear however, if stabilization of PINK1 by 
PARKIN is dependent on PARKIN ubiquitination activity [165]. PARKIN has been shown to 
conjugate K6, K11, K63 [166] and even K48 [167] chains on damaged mitochondria as fast 
as 1 hour after loss of mitochondrial potential, in a ligation process dependent on its catalytic 
cysteine and phosphorylation by PINK1 on its UBL domain. This increase of ubiquitination by 
PARKIN has been quantified as a 6-fold increase 1 hour after depolarization of mitochondria 
[167]. The DUB USP30 acts as a regulator of mitophagy by counteracting PARKIN 
ubiquitination of mitochondria and this despite phosphorylation of ubiquitin chains [168]. In 
vitro, USP30 has been shown to have a strong preference for K6 and K11 ubiquitin chains on 
the OMM [166]. In vivo, USP30 seems to be much more promiscuous and removes all 
ubiquitin chains conjugated by PARKIN [167]. Other DUBs have also been described as 
regulator of PARKIN-dependent mitophagy, such as USP8 [62], USP15 [169] and Ataxin-3 
[170]. Upon ubiquitination by PARKIN, autophagy adaptors are recruited to depolarized 
mitochondria: mostly SQSTM1/p62 [171] and NBR1 [172], although TAX1BP1 and NDP52 
have been found as interactors of PARKIN [173]. Moreover, PARKIN overexpression recruits 
also OPTN to damaged mitochondria [174]. The LC3-interacting region (LIR) motifs of these 
autophagy adaptors then recruit LC3 bound to the omegasome/autophagosome, ultimately 
leading to degradation of the defective mitochondria in lysosomes. Among the mitochondrial 
proteins polyubiquitinated by PARKIN are Mitofusin (MFN) 1/2 and mitochondrial Rho GTPase 
(RHOT) 1/2 [173]. These GTPases mediate mitochondrial clustering and fusion in the case of 
MFN and mitochondria trafficking in the case of RHOT0. Their polyubiquitination results in 
separation of the mitochondria from the cytoskeleton (stopping their axonal transport in 
neurons for example), fragmentation of the mitochondrial network [175] and separation from 
the ER before undergoing degradation [176]. However, this idea of separation of mitochondria 
from the ER during mitophagy would go against previous studies indicating that contact sites 
between the mitochondria and the ER are crucial for autophagosome formation [177], unless 
these events are sequential: first autophagosomes are recruited, then loss of contact between 
ER and mitochondria occurs. Regarding RHOT, phosphorylation on its residues T298 and 
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T299 inhibits ubiquitination by PARKIN and mitochondrial arrest, indicating that mitophagy 
could be halted via the phosphorylation state of certain OMM proteins [175]. Other proteins 
from the OMM have been found as candidates for ubiquitination by PARKIN, such as TOM20, 
TOM70 and fission proteins (FIS1 and TBC1D15) [173]. Interestingly, the same study by 
Sarraf et al. indicates that PARKIN interacts with proteasome subunits (PSMC1, 2, 3, 5 and 
PSMD 8 and 13) and proteins involved in proteasomal degradation such as VCP/p97 [173]. 
This finding corroborates previous observations of PARKIN interacting with the proteasome 
[178] and being involved in recruitment of the UPS for degrading OMM proteins such as 
TOM20 and TOM70 [172,179], prior to removal of the whole mitochondrion by mitophagy. 
Another feedforward loop running downstream of PINK1 and PARKIN activation involves 
TBK1, a serine/threonine kinase phosphorylating OPTN, NDP52 and p62 [180–182].  
Phosphorylation of these autophagy adaptors by TBK1 increases their affinity towards 
ubiquitin chains, which promotes mitophagy.  
 
1.8.2.3 PARKIN-independent mitophagy 
 
There is growing evidence that PARKIN is not the only E3 involved in mitophagy. Gp78 [183], 
SMURF1 [184], SIAH-1 [185] and ARIH1 [186]  have all been found to regulate mitophagy 
independently of PARKIN but in a PINK1-dependent manner, by ubiquitinating mitochondrial 
substrates and recruiting autophagy adaptors such as OPTN, NDP52 and SQSTM1/p62 [187]. 
Although these E3 do not need PARKIN to induce mitophagy, they function in a similar way 
as PARKIN, requiring the activation of PINK1 upstream of their own activation, consequently 
activating the PINK1 feedforward loop. 
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1.9 TARGETED UBIQUITINATION 
 
Since ubiquitination is a key post-translational modification for protein turnover and trafficking, 
it should come as no surprise that several targeted ubiquitination systems have been 
engineered to harness protein degradation in order to target proteins of clinical interest for 
degradation. Among such approaches are proteolysis targeting chimeras and ubiquibodies. 
 
1.9.1 PROTACs 
 
Proteolysis targeting chimeras (PROTACs) [188,189] are the most successful approach 
aiming at targeting specific proteins for degradation. PROTACs are able to bind a specific E3 
ligase and the target protein, thereby bringing both proteins close enough for the target to be 
ubiquitinated. A  PROTAC is a ligand for the target to be degraded, fused to a linker and a 
ligand for an E3 [190]. Most PROTACs are based on a hypoxia-inducible factor-1 alpha 
(HIF1a) moiety, which can recruit the von Hippel-Lindau (VHL)-cullin-RING ligase, leading to 
ubiquitination and proteasomal degradation of the target. PROTACs are based on a peptide 
scaffold and therefore of larger size than most small molecules. The HIF1a moiety, however, 
has been brought down to the minimal molecular weight of 400 Da by conserving the 
hydroxyproline moiety necessary to VHL binding, allowing better tissue distribution of the 
PROTAC [191]. 
 
1.9.2 Ubiquibodies 
 
Another more recent approach to target proteins for degradation is the usage of ubiquibodies 
[192]. The idea behind ubiquibodies is to exploit the E3 CHIP (carboxyl terminus of Hsc70-
interacting protein) to target a specific protein for degradation by replacing the binding domain 
of CHIP by an intrabody or monobody specific of the target. This technique is more generic 
than PROTACs because it does not require endogenous E3 and a designed ligand to bind 
both the target and the E3. The molecular weight of ubiquibodies is also larger than the one 
of PROTACs, making it less suitable in a therapeutic setting. 
 
1.9.3 Limitations of current targeted ubiquitination system 
 
One major limitation of both approaches is their focus on inducing proteasomal degradation 
of potential therapeutic targets. As it has been shown in previous parts of this introduction, 
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many types of ubiquitin chain topographies exist, and they do not always target for 
proteasomal degradation. Although targeting specific proteins of therapeutic interest is 
clinically relevant, these approaches cannot be used to deepen our understanding of the 
function of various ubiquitin-linkages. This is especially the case of PROTAC, which uses 
endogenous E3 to degrade an endogenous substrate, making it difficult to interpret results. 
Furthermore, the ubiquibody would still target an endogenous substrate, which is still subject 
to many different regulations in the cell. By targeting specific endogenous substrates, these 
techniques also have the caveat that off-target effects may occur. Therefore, one system that 
would clarify the role of specific ubiquitin chains in cells should be independent from 
endogenous regulations as possible and as such, no ubiquitination of the target by other 
unknown E3s should happen in order to make interpretation of results clearer. It is also 
desirable that the system is modular and easy to modify in order to generate different ubiquitin 
chain types. 
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2 AIM OF THE STUDY 
 
The aim of this study was to develop a ubiquitination system where an engineered ubiquitin 
ligase can assemble K63 ubiquitin chains on a fluorescent substrate when brought in close 
proximity to a substrate-of-interest. Subsequently, we wanted to exploit this system to 
generate ubiquitin chains on the surface of mitochondria and investigate mitochondrial 
clustering and mitophagy (Paper I). Secondly, this work investigated another ubiquitin-
dependent proteolysis in the nucleus in the context of the Hutchinson-Gilford progeria 
syndrome (HGPS). We aimed at verifying if the ubiquitin-proteasome system was impaired in 
human cells expressing a mtated version of lamin A, progerin (Paper II). 
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3 METHODOLOGICAL CONSIDERATIONS 
 
3.1 HELA CELLS STABLY EXPRESSING SOLUBLE AND MITOCHONDRIAL 
GFP SUBSTRATE (PAPER I) 
 
HeLa is a human cervical cancer cell-line from Henrietta Lacks, which is one of the most 
common human cell lines used in cell biology. HeLa cells are cultured in Dulbecco’s modified 
Eagle’s medium, supplemented with 10% fetal calf serum. To generate HeLa cells stably 
expressing GFP-DmrA and mito-GFP-DmrA (see paper I), we started by transfecting our 
pCMV-IRES-puro-GFP-DmrA or mito-GFP-DmrA plasmid into HeLa cells. The transfection 
reagent used was Lipofectamine® 2000 (Invitrogen), which forms liposomes encapsulating 
the plasmid DNA and allow it to cross the cell membrane. Transfection is carried out in a T25 
flask with Dulbecco’s modified Eagle’s medium devoid of fetal calf serum, because serum can 
interfere with interactions between the DNA-liposome complexes and the cell membrane, thus 
decreasing transfection efficiency. Forty-eight hours after transfection, selective pressure was 
applied to the cells by adding 1 µg/mL of Puromycin to the cell culture medium in order to 
select cells that integrated the plasmid into their genome. The 1 µg/mL dose had been 
determined as the minimum dose killing 100% of the HeLa cells after 5 days. The selection 
process goes on for 10 days during which the culture medium with 10% serum and 1 µg/mL 
puromycin is changed every third day. After these 10 days, the cells are detached from the 
surface of the flask using trypsin/EDTA and diluted to a concentration of 1 cell/mL. These cells 
were then plated on several 24-well plates, 500 µL per well (0.5 cells per well on average). 
After two weeks of culture in medium with puromycin, the expanded stable monoclonal mito-
GFP-DmrA cells displaying moderate GFP fluorescence under an epifluorescence 
microscope were frozen.  
 
One clone was further expanded and sorted using flow cytometry. Flow cytometry is a 
common laser-based method, allowing for sorting of single cells based on their fluorescence 
(either due to expression of a fluorescent protein or fluorescent antibodies), size and 
granularity. One cell at a time is passing through a capillary and is exposed to a set of lasers. 
In our case, GFP fluorescence was measured together with the granularity of the cell using 
sideward scatter (scattering of light around the cell at a 90° angle) and the size of the cell using 
forward scatter (scattering of light around along the path of the laser). This sorting allowed us 
to select HeLa cells exhibiting moderate GFP fluorescence because we anticipated that high 
expression of mito-GFP-DmrA might be detrimental to cellular growth and fitness of the cells. 
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3.2 CONFOCAL LASER SCANNING MICROSCOPY (PAPER I AND II) 
 
Confocal laser scanning microscopy is a laser-based type of fluorescence microscopy using 
a pinhole to obtain high-resolution images, especially along the z-axis, by detecting light 
coming from the focal plane only. The light coming from planes out of focus does not pass 
through the pinhole and therefore does not reach the detectors. The detectors used in most 
confocal microscopes are photomutiplier tubes (PMT). These PMTs convert photons into an 
amplified electric (analog) signal, which is converted next into a digital signal, resulting in pixel 
intensities i.e. an image. Multiple fluorophores i.e. “colors” can be detected by using of an 
acousto-optic tunable filter (AOTF) and choosing carefully a set of fluorophores for the 
specimen (a recombinant fluorescent protein or coupled to antibodies) a set of lasers and 
PMTs. In both papers, images were acquired using a LSM510 Meta (Carl Zeiss) confocal laser 
scanning microscope with Plan Apochromat 63x/1.40 DIC oil immersion objective (Carl Zeiss), 
with a resolution of 1024 x 1024 pixel. For paper I, nuclei were counterstained using Hoechst 
33342, which binds DNA and has a maximum excitation peak at 361 nm, while emitting a blue 
fluorescence at a maximum of 486 nm. The EGFP (Enhanced Green Fluorescent Protein) 
recombinant proteins in both papers have a maximum excitation peak at 488 nm and a 
maximum emission peak at 509 nm (green). The mCherry used in paper I has a maximum 
excitation peak at 587 nm and a maximum emission peak at 610 nm (red). HcRed1 used in 
paper II has a slightly different spectrum from mCherry: its maximum excitation peak is at 588 
nm and its maximum emission peak is at 618 nm (far red). The cells were fixed in 4% 
paraformaldehyde prior to mounting on glass slides in Mowiol mounting medium. Using such 
a mounting medium is important for optimum imaging by avoiding a mismatch of the refraction 
index of the immersion medium (oil) with the mounting medium, avoiding autofluorescence 
and reducing photobleaching of the fluorophores. 
 
3.3 WESTERN BLOT (PAPER I) 
 
Western blot, also known as immunoblot, is a common molecular biology method for detection 
of proteins by using antibodies. One limitation of western blot is therefore the quality and 
performances of antibodies specific for the proteins-of-interest. It is also important to keep in 
mind that western blots are only semi-quantitative, meaning that it can give us ratios that 
describe differences and fluctuation of a protein levels in different conditions but not give a 
precise quantity of proteins in a sample. Samples can consist of purified proteins-of-interest 
or cell lysate. Sample preparation is followed by separation of proteins by SDS-PAGE (sodium 
dodecyl sulfate-polyacrylamide gel electrophoresis). SDS is used to denature proteins 
(together with boiling the sample) and charge them negatively. Negatively charged proteins 
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will then follow an electric field during the electrophoresis and migrate towards the bottom of 
the gel, where is located the positive pole of the system. The distance traveled by proteins 
depends on their mass and the density of the polyacrylamide gel, not on the proteins’ charge, 
as all proteins are similarly denatured and charged by SDS. The mass of proteins can be 
estimated when compared to a molecular marker of known weight. Proteins are then 
transferred from the polyacrylamide gel to a membrane made of nitrocellulose or 
polyvinylidene difluoride (PVDF). The transfer is followed by a blocking step. The aim of the 
blocking step is to reduce non-specific binding of antibodies to the membrane. Different type 
of blocking solutions can be used depending on the antibodies, such as nonfat milk powder or 
bovine serum albumin in phosphate-buffer saline (PBS). Then, the membrane is incubated in 
a primary antibody solution. The primary antibody is specific of the protein of interest and can 
be from monoclonal or polyclonal origin. Monoclonal antibodies are specific for an epitope on 
the protein-of-interest and polyclonal antibodies can recognize multiple epitopes, which might 
confer them a higher sensitivity, although binding to another protein beside the one of interest 
is more likely. After each incubation with an antibody, it is important to wash the membrane 
with PBS or TBS (depending on the antibody), to reduce non-specific binding of the antibody. 
The membrane is then incubated in a secondary antibody solution. The secondary antibody 
is coupled with Horseradish Peroxidase (HRP) and is specific of the primary antibody, which 
amplifies the signal. A final detection step is carried out, during which a substrate for the HRP 
is added to the membrane. Oxidation of the substrate by HRP ensues, leading to light 
emission, which is then enhanced by various chemicals in the detection reagent. The emission 
of light and its subsequent amplification is known as Enhanced Chemiluminescence (ECL). 
 
3.4 IMMUNOPRECIPITATION (PAPER I) 
 
Immunoprecipitation is commonly used in molecular biology to study the interaction between 
proteins, post-translational modifications of a protein of interest or purification of proteins. 
During an immunoprecipitation, cells are first lysed on ice, either in a denaturing buffer 
abolishing protein/protein interaction or a native buffer preserving such interactions. In our 
case, the native buffer is made of 10 mM Tris/Cl pH 7.5; 150 mM NaCl; 0.5 mM EDTA and 
0.5% NP-40 while the denaturing buffer does not contain NP-40 but instead 1% SDS. The 
difference is that NP-40 is a mild nonionic detergent, sufficient to open cells and solubilize 
membrane proteins, while preserving protein/protein interaction and keeping proteins in their 
native conformation. SDS on the other hand, is a strong ionic detergent known for denaturing 
proteins, thus reducing protein/protein interaction. Soluble and insoluble proteins are 
separated by centrifugation, the soluble proteins are then incubated with antibodies coupled 
to beads, in our case: GFP-Trap® _A or RFP-Trap® _A (ChromoTek GmbH, Germany), which 
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are made of cross-linked 4% agarose beads coupled with anti-GFP or anti-RFP monoclonal 
antibodies from alpaca (Vicugna pacos). The beads are then spun down and boiled at 95°C 
into 2X SDS sample buffer (125 mM Tris/Cl pH 6.8, 20 % glycerol, 4 % SDS, 10 mM DTT and 
0.02 % bromophenol blue) for 10 minutes to detach the pulled-down proteins from the beads. 
An immunoprecipitation is usually followed by a western blot in order to detect proteins and/or 
post-translational modifications. 
 
3.5 PROTEIN PURIFICATION AND IN VITRO UBIQUITINATION ASSAY 
(PAPER I) 
 
In vitro ubiquitination assays are used for characterizing ubiquitination enzymes (E1, E2 and/or 
E3) and their substrates in a simple and minimalistic system. In paper I, we used ubiquitination 
assays to study the functionality of the engineered E3 ligase ProxE3 and the type of ubiquitin 
linkages assembled on the substrate of ProxE3. Purified proteins are necessary for 
ubiquitination assays and can either be bought from a provider or purified. ProxE3, its GFP 
substrates and untagged ubiquitin mutants were purified from E. coli bacteria (BL21[DE3] for 
the fluorescent proteins and Rosetta[DE3]pLys for the ubiquitin mutants). The bacteria are first 
lysed, followed by immunoprecipitation (see above) for the purification of ProxE3 and its GFP 
substrate because these proteins are “tagged” with fluorescent proteins, which were used for 
immunoprecipitating the recombinant proteins. For untagged ubiquitin mutants, pH of the cell 
lysate is brought down to 4.5, which precipitates many proteins but not ubiquitin. The proteins 
that remain in suspension, including ubiquitin, are then concentrated by dialysis followed by 
spinning in 3.0 kDa Molecular Weight Cut-Off centricon tubes. Untagged ubiquitin mutants 
that are purified by this procedure are of sufficient in purity for in vitro ubiquitination assays 
while not being of the highest purity. 
 
The ubiquitination assay itself was carried out in a ubiquitination buffer (25 mM Tris-HCl pH 
7.6, 5mM MgCl2, 100 mM NaCl, 2 μM DTT) at 37°C with 0.2 µM of ProxE3/ProxE3* and GFP 
substrate and 0.5 μM AP21967 dimerizer. This first step allows dimerization of ProxE3 with its 
GFP substrate. Then, the ubiquitylation reaction was started by adding 200 nM UbE1, 1 μM 
UbcH5C, 1.2 μM untagged or HA tagged (Boston biochem) ubiquitin and 2 mM ATP to the 
pre-dimerization mix. The reaction was stopped by adding one volume of 2x SDS-PAGE 
sample buffer and boiling at 95°C for 10 minutes, followed by western blot (see above). 
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4  RESULTS AND DISCUSSION 
 
4.1 PAPER I 
 
The first paper aimed at developing and testing a molecular tool, ProxE3, for investigating the 
role of K63 polyubiquitination in specific organelles. The ProxE3 recombinant protein has been 
generated from the fusion of a FRB dimerization domain at the N-terminus, a NEDD4-1 HECT 
domain in the C-terminus and a mCherry fluorescent protein in the middle. The target of 
ProxE3 is a GFP recombinant protein with GFP at the N-terminus, fused with a FKBP12 
dimerization domain in the center and a linker containing 5 lysines in the C-terminus. This GFP 
substrate is largely inherent in mammalian cells and is therefore ideal to study the effect of a 
specific ubiquitin linkage on the fate of a protein. Upon treatment with the rapalog AP21967, 
the FRB and FKBP12 domains interact, bringing ProxE3 in close proximity of its GFP 
substrate. We have shown that it is possible to conjugate specifically K63-linked polyubiquitin 
on the GFP target in HeLa cells expressing both proteins and in vitro. Such ubiquitination of 
the GFP substrate does not lead to its degradation, be it by the proteasome or autophagy.  
 
Interestingly, ProxE3 was able to auto-ubiquitinate both in vitro and in cells, leading to its 
proteasomal degradation in the latter, as proteasomal inhibitor MG132 stabilizes ProxE3. This 
is in line with the literature indicating that the HECT domain from the NEDD4 family tend to 
auto-ubiquitinate in absence of a substrate when it is expressed without the regulatory WW or 
C2 domains. However, since ProxE3 conjugates K63 ubiquitin linkages, it is uncertain how it 
can be degraded by the proteasome. It is possible that K63-linked ubiquitin chains conjugated 
by ProxE3 on itself can be edited by other E3s, as it is known to happen to Mdm2, GP78 and 
CBL proteins [193]. Also, the HECT E3 HUWE1 has been shown to branch K63 ubiquitin 
chains with K48-linkages [194], although this has not been shown for any endogenous E3s. 
Proteins such as A20 could also be candidates. A20 is known to bind K63-linked ubiquitin 
chains and has a DUB activity towards this linkage. However, it also has a K48 ligase activity 
[195]. This allows A20 to remove K63-linked ubiquitin chains from its target, RIP1, and replace 
them by K48-linked ubiquitin, leading to RIP1 proteasomal degradation [196]. 
 
The GFP substrate was expressed in a specific organelle: the mitochondrion, by adding a 
mitochondrial transmembrane domain in C-terminus. ProxE3 was also able to conjugate K63-
linked polyubiquitin on the mitochondrial GFP substrate. Although it did not lead to mitophagy, 
even after depolarization of mitochondria with CCCP, clustering of mitochondria was 
observed. The absence of mitophagy despite the presence of K63-linked ubiquitin chains on 
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the GFP mitochondrial substrate in depolarizing conditions could be explained by an 
insufficient amount of K63 ubiquitin on the mitochondria to trigger mitophagy. This amount of 
K63 ubiquitination might be enough to trigger peri-nuclear clustering of mitochondria in our 
artificial system however. Another related explanation would be that the PINK1 feedforward 
loop is insufficient in our system. Even in PARKIN independent pathways, the PINK1 
feedforward loop is required to recruit more E3 ligases and phosphor-ubiquitin to the 
mitochondria. However, ProxE3 being an exogenous recombinant protein, it is not further 
recruited by the PINK1 feedforward loop and functional PARKIN might be present at a too low 
level in HeLa cells to sustain mitophagy signals [197,198]. It could also be that other types of 
ubiquitin chains are required to trigger mitophagy. In fact, PARKIN is known to conjugate K48, 
K6 and K11 linkages on top of K63 linkages, while our ProxE3 conjugates only K63-linked 
polyubiquitin. Finally, ubiquitination of a specific mitochondrial protein might be necessary to 
trigger mitophagy. 
 
The novelty of this work is a new modular tool for studying the role of specific ubiquitin linkages 
on organelles, without the need of targeting a specific endogenous substrate. This paper also 
reaffirms that E3s are tightly regulated and can potentially be targeted by other E3 or ubiquitin 
editing proteins. We also give evidence that an increase of K63 chains on a mitochondrial 
substrate is not enough in itself to trigger mitophagy but can trigger clustering of dysfunctional 
mitochondria. 
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4.2 PAPER II 
 
Paper II focused on HGPS, a rare genetic disorder leading to premature aging in children. The 
model developed in this study is an inducible transgenic mouse model expressing the most 
common human lamin A mutation responsible of HGPS, LMNA c.1824C>T. The resulting 
nuclear protein, which is commonly referred to as progerin, is a truncated pre-lamin A lacking 
50 amino acids. This work focused primarily on potential effects of progerin in the brain of 
HGPS mice, although no detrimental effects were observed in the brain and behavior of 
animals even after 90 weeks of expression of the transgene. Nonetheless, tissue specific 
accumulation of progerin has been observed in neurons of the frontal cortex and hippocampus 
of mice expressing the transgene for 90 weeks compared to those expressing it for 20 weeks. 
Furthermore, severe distortion of the nucleus (multiple lobulations and irregular extensions) of 
hippocampal neurons has been observed in transgenic mice compared to wild-type. These 
observations led to investigating if the ubiquitin-proteasome system was compromised in cells 
of transgenic mice, due to accumulation of progerin. To explore the potential impairment of 
the UPS due to progerin overexpression, a human melanoma cell-line (MelJuSo) stably 
expressing a GFP reporter substrate of the UPS was used. No accumulation of the GFP 
reporter substrate was observed in the stable cell line overexpressing progerin compared to 
those overexpressing lamin A. In comparison, treatment of these cells with MG132, a 
proteasome inhibitor, lead to accumulation of the GFP substrate. These experiments 
suggested that the UPS remains functional, even when progerin is overexpressed, which 
contradicts previous studies reporting impairment of the catalytic activity of the proteasome by 
progerin in fibroblasts of HGPS patients [199]. The lack of ubiquitin-rich lamin A, progerin or 
even Tau inclusions in cortical and hippocampal neurons of 90-week HGPS mice compared 
to WT, further support the hypothesis of an absence of UPS impairment in HGPS mice. The 
novelty of this paper is to imply that there is no global impairment of the UPS in cells expressing 
progerin. 
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5 CONCLUDING REMARKS 
 
Overall, this work shows how tightly regulated and robust ubiquitin-dependent cellular 
processes are. On one hand, expression of the mutated form of a major component of the 
nuclear envelope, lamin A/progerin, does not affect the capacity of the UPS to degrade its 
target proteins, despite the accumulation of this mutated protein in the nucleus under 
pathological conditions. On the other hand, adding K63-linked ubiquitin chains on the surface 
of mitochondria is insufficient to trigger mitophagy, even after depolarization of mitochondria. 
In both cases, lack of robustness and regulation of these pathways would lead to cell death: 
by proteotoxic stress in the first case and by rapid degradation of the mitochondrial network in 
the second case. 
 
Although K63 ubiquitination is necessary for mitophagy, it is not sufficient. Commitment to the 
mitophagy route might require more ubiquitin chains, different type of ubiquitin chains or further 
activation of PINK1 and amplification of the signal. Despite the lack of mitophagy triggered by 
the ProxE3 system, this tool can be used for conjugation of specific ubiquitin chains on an 
exogenous substrate in cells. The present work has only used this tool in the context of 
mitophagy but it could be of use in different cellular contexts, such as for studying 
ubiquitination of integral inner nuclear membrane proteins. The degradation of integral inner 
nuclear membrane proteins remains elusive and has mostly been studied in yeast so far 
[81,82]. The ProxE3 tool could also be used to study the impact of specific ubiquitin-linkages 
on protein aggregates. 
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